275 related articles for article (PubMed ID: 29339815)
1. MCL-1 is a prognostic indicator and drug target in breast cancer.
Campbell KJ; Dhayade S; Ferrari N; Sims AH; Johnson E; Mason SM; Dickson A; Ryan KM; Kalna G; Edwards J; Tait SWG; Blyth K
Cell Death Dis; 2018 Jan; 9(2):19. PubMed ID: 29339815
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
3. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
[TBL] [Abstract][Full Text] [Related]
4. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Merino D; Whittle JR; Vaillant F; Serrano A; Gong JN; Giner G; Maragno AL; Chanrion M; Schneider E; Pal B; Li X; Dewson G; Gräsel J; Liu K; Lalaoui N; Segal D; Herold MJ; Huang DCS; Smyth GK; Geneste O; Lessene G; Visvader JE; Lindeman GJ
Sci Transl Med; 2017 Aug; 9(401):. PubMed ID: 28768804
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
7. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
Anderson GR; Wardell SE; Cakir M; Crawford L; Leeds JC; Nussbaum DP; Shankar PS; Soderquist RS; Stein EM; Tingley JP; Winter PS; Zieser-Misenheimer EK; Alley HM; Yllanes A; Haney V; Blackwell KL; McCall SJ; McDonnell DP; Wood KC
Sci Transl Med; 2016 Dec; 8(369):369ra175. PubMed ID: 27974663
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
[TBL] [Abstract][Full Text] [Related]
10. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Williams MM; Lee L; Werfel T; Joly MMM; Hicks DJ; Rahman B; Elion D; McKernan C; Sanchez V; Estrada MV; Massarweh S; Elledge R; Duvall C; Cook RS
Cell Death Dis; 2018 Jan; 9(2):21. PubMed ID: 29343814
[TBL] [Abstract][Full Text] [Related]
12. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function.
Campbell KJ; Mason SM; Winder ML; Willemsen RBE; Cloix C; Lawson H; Rooney N; Dhayade S; Sims AH; Blyth K; Tait SWG
Cell Death Differ; 2021 Sep; 28(9):2589-2600. PubMed ID: 33785871
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
[TBL] [Abstract][Full Text] [Related]
15. Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers.
Louault K; Bonneaud TL; Séveno C; Gomez-Bougie P; Nguyen F; Gautier F; Bourgeois N; Loussouarn D; Kerdraon O; Barillé-Nion S; Jézéquel P; Campone M; Amiot M; Juin PP; Souazé F
Oncogene; 2019 Apr; 38(17):3261-3273. PubMed ID: 30631150
[TBL] [Abstract][Full Text] [Related]
16. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
[TBL] [Abstract][Full Text] [Related]
17. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
[TBL] [Abstract][Full Text] [Related]
19. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of miR-320 associated with cancer progression and cell apoptosis via targeting Mcl-1 in cervical cancer.
Zhang T; Zou P; Wang T; Xiang J; Cheng J; Chen D; Zhou J
Tumour Biol; 2016 Jul; 37(7):8931-40. PubMed ID: 26753959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]